Risks and benefits: new concepts of treatment of late-onset hypogonadism / 中华男科学杂志
National Journal of Andrology
;
(12): 483-489, 2014.
Article
in Chinese
| WPRIM
| ID: wpr-309687
ABSTRACT
Late-onset hypogonadism (LOH) is a clinical and bio-chemical syndrome associated with advancing age in males and seriously affects the quality of life of some of the patients. A classical therapeutic option for LOH is testosterone supplementary treatment (TST). Its effectiveness has been verified, whereas its long-term safety remains to be further evaluated. With deeper insights into LOH, many new therapeutic strategies have been proposed, which include the treatments with gonadotropins, testosterone precursors (such as dehydroepiandrosterone [DHEA]), non-aromatizable androgens (such as dihydrotestosterone [DHT]), antiestrogens (such as aromatase inhibitors and estrogen receptor antagonists), and Chinese medicine. Meanwhile, studies on the transplantation of Leydig stem cells, selective androgen receptor modulators (SARMs), and selective estrogen receptor beta (ERbeta) agonists have shed new light on the treatment of LOH.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
General Surgery
/
Testosterone
/
Therapeutics
/
Therapeutic Uses
/
Drug Therapy
/
Hypogonadism
Type of study:
Etiology study
Limits:
Humans
/
Male
Language:
Chinese
Journal:
National Journal of Andrology
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS